<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652921</url>
  </required_header>
  <id_info>
    <org_study_id>DS-04/2020</org_study_id>
    <nct_id>NCT04652921</nct_id>
  </id_info>
  <brief_title>Creatine-Guanidinoacetic Acid Supplementation for Sarcopenia (CREGAAS)</brief_title>
  <acronym>CREGAAS</acronym>
  <official_title>The Effects of 6-month Supplementation With Creatine and Guanidinoacetic Acid on Biomarkers of Sarcopenia in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Novi Sad, Faculty of Sport and Physical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Novi Sad, Faculty of Sport and Physical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive&#xD;
      pathological facet of this condition, and this might be approached with targeted therapies in&#xD;
      aim to restore creatine homeostasis in target tissues. Among potential therapeutic&#xD;
      candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that&#xD;
      may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine&#xD;
      mixture was found to be superior than creatine itself to effectively improves bioenergetics&#xD;
      in the human brain and muscle in healthy humans, perhaps due to the unique transportability&#xD;
      features of this combination. Here, we plan to evaluate does creatine-GAA supplementation&#xD;
      affects various biomarkers of sarcopenia in elderly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in muscular strength</measure>
    <time_frame>Baseline vs. 6 months post-intervention</time_frame>
    <description>Baseline vs. 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle mass</measure>
    <time_frame>Baseline vs. 6 months post-intervention</time_frame>
    <description>Baseline vs. 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle metabolites evaluated with MR spectroscopy</measure>
    <time_frame>Baseline vs. 6 months post-intervention</time_frame>
    <description>Baseline vs. 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance evaluated with Mini-Mental State Exam test</measure>
    <time_frame>Baseline vs. 6 months post-intervention</time_frame>
    <description>Baseline vs. 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatine</measure>
    <time_frame>Baseline vs. 6 months post-intervention</time_frame>
    <description>Baseline vs. 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Creatine-guanidinoacetic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Creatine-guanidinoacetic acid</intervention_name>
    <description>A dietary supplement provided as powder dissolved in a glass of water</description>
    <arm_group_label>Creatine-guanidinoacetic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>A dietary supplement provided as powder dissolved in a glass of water</description>
    <arm_group_label>Inulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 70 years&#xD;
&#xD;
          -  Free of acute disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of dietary supplement use during the past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Applied Bioenergetics Lab at Faculty of Sport and PE</name>
      <address>
        <city>Novi Sad</city>
        <state>Vojvodina</state>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

